| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Previous Article | Next Article ![]()
Molecular and Cellular Biology, December 2007, p. 8760-8769, Vol. 27, No. 24
0270-7306/07/$08.00+0 doi:10.1128/MCB.01415-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

University of California, San Francisco, Department of Biochemistry and Biophysics, San Francisco, California 94158-2200
Received 7 August 2007/ Returned for modification 3 September 2007/ Accepted 30 September 2007
| ABSTRACT |
|---|
|
|
|---|
7,200 knockdowns for their effects on GFP-MSL2 distribution. One factor identified is the zinc finger protein Zn72D. In its absence, the MSL complex no longer coats the X chromosome. We demonstrate that Zn72D is required for productive splicing of the transcript for the MSL protein Maleless, explaining the dosage compensation defect. However, Zn72D is required for the viability of both sexes, indicating its functions are not sex specific. Consistent with this, Zn72D colocalizes with elongating RNA polymerase II, implicating it as a more general factor involved in RNA metabolism. | INTRODUCTION |
|---|
|
|
|---|
The MSL complex is composed of five proteins, MSL1, MSL2, MSL3, MLE (Maleless), and MOF (Males absent on the first), and two noncoding RNAs, roX1 and roX2. All MSL proteins and at least one roX RNA must be expressed for the localization of the entire MSL complex to the X chromosome and for proper X-linked gene expression. msl2 mRNA is translated exclusively in male cells, ensuring sex-specific deployment of the MSL complex (5, 19, 29). MSL2 stabilizes MSL1, and these two proteins, in the absence of any one of the other MSL proteins, bind to approximately 35 sites along the length of the X chromosome (28, 37, 40). When MSL3, MLE, MOF, and at least one of the roX RNAs are also expressed, the complete complex forms and localizes to additional sites on the X chromosome. This was originally proposed to be the result of spreading of the complex from the
35 sites to additional sites along the X chromosome (28, 37, 40) and was more recently proposed to be the result of the complex binding first to
35 high-affinity sites and then to additional lower-affinity sites (10, 12, 15, 20, 44). MOF, a histone acetyltransferase, hyperacetylates histone H4 at lysine 16, resulting in the twofold increase in expression of X-linked genes (1, 49). The localization and function of each component of the complex are highly regulated. For example, the acetyltransferase activity of MOF and the helicase and/or the ATPase function of MLE are both required for the complex to associate with the X chromosome in regions beyond the chromatin entry sites (21). MOF and MLE, as well as MSL3, require RNA for their localization to the X chromosome, and in turn, the roX RNAs are stabilized by the localization of the MSL complex to the X chromosome (2, 8, 40, 46). In addition, transcription of roX RNAs is controlled by the MSL proteins (4, 34, 45). Together, these data uncover a series of interactions between components of the MSL complex that are required to ensure the complex's correct localization and activity.
While the translational regulation of msl2 by sex-lethal proteins and the regulation of roX transcription by the MSL proteins are well documented, the factors that regulate expression of the remaining components of the MSL complex remain largely uncharacterized. We carried out an RNA interference (RNAi) screen to identify novel factors involved in the localization of the MSL complex to the X chromosome. Using this screen, we identified the zinc finger protein Zn72D as a new protein required for MSL complex localization and dosage compensation. Zn72D is essential for development in both males and females. It is not enriched on the X chromosome in males but rather colocalizes with elongating RNA polymerase II. We found that Zn72D is required to promote the production of the correctly spliced form of mle mRNA, thus elucidating its role in dosage compensation. Together, these data suggest that Zn72D may have a more general role in RNA metabolism and that it indirectly regulates dosage compensation.
| MATERIALS AND METHODS |
|---|
|
|
|---|
RNAi screen.
The RNAi library was constructed as described previously (16), and additional information about this library can be found at http://rnai.ucsf.edu. Double-stranded RNAs (dsRNAs) were added to S2 cells (
15 µg/ml) in 50% conditioned-50% fresh Schneider's medium in a 96-well format. Four days later, cells were transferred to glass-bottom imaging plates (Greiner Bio-One) coated with concanavalin A (0.5 mg/ml) and allowed to settle for 1 h. Cells were then fixed in 1% formaldehyde in 1x phosphate-buffered saline (PBS) for 10 min, and washed three times with 1x PBS, and Fluoromount-G (Southern Biotech) was added. A visual screen was performed to assay for the loss of the GFP-MSL2-coated X chromosome, using a Nikon TE-200 inverted microscope. All dsRNAs produced for subsequent RNAi experiments were produced as described previously (16). The following primers were used to make the dsRNAs: msl1 was made with the primers RNAi1.1-msl1 (GGGCGGGTAATTACCTTTTGGAATTGGA) and RNAi1.2-msl1 (GGGCGGGTGGTGGACTGATGGTTGGCTA); mle (in the RNAi library) was made with the left primer GGGCGGGTTTATGGCTTCGTACTCTAGCACC and the right primer GGGCGGGTAAGTTAAGCCAGTTGTCAACGC; an alternative mle dsRNA was made with primers mleRNAi#2F (GGGCGGGTCCCAAAAATCGCCAGCGG) and mleRNAi#2R (GGGCGGGTCGCGAATGTTGTTCGTCTGC); and the Zn72D3'UTR was made using primers Zn72D3'UTR(s) (GGGCGGGTGCGGCGAGAATAGGTTATATAC) and Zn72D3'UTR(as) (GGGCGGGTCCGCTTCGTTCTAGTATTTGTG).
Immunofluorescence. S2 cells were allowed to settle on concanavalin A-treated coverslips for 1 h and then fixed in 3.7% formaldehyde-0.1% Triton X-100 in 1x PBS for 5 min, washed twice in 0.1% Triton X-100, and blocked for 30 min in 0.1% Triton X-100-5% goat serum-1x PBS, and primary antibodies were added overnight at 4°C. Polytene chromosomes were prepared following the online protocol (http://www.epigenome-noe.net/researchtools/protocol.php?protid=1). Polytene spreads were stained for 1 h at 37°C for MSL1 and MLE staining and at 4°C overnight for polymerase II (Pol II)-stained chromosomes. The antibodies were used at the following dilutions: rabbit anti-MOF at 1:500, rabbit anti-MSL1 at 1:200, guinea pig anti-MLE at 1:200 (gifts from J. Lucchesi), rabbit anti-GFP (catalog no. ab290-50; Abcam) at 1:750, mouse anti-GFP (catalog no. JL-8; Clontech) at 1:500, mouse anti-HA (catalog no. HA.11; Covance) at 1:200, Pol II antibody H5 and H14 at 1:50 each, and mouse anti-c-Myc (catalog no. sc-40; Santa Cruz Biotechnology) at 1:500. Coverslips were washed twice in 0.1% Triton X-100 and blocked for 5 min, and secondary antibodies (all from Vector Laboratories; used at a dilution of 1:200, except for anti-immunoglobulin M, which was from Jackson Immunologicals and was used at a dilution of 1:1,000) were applied for 45 min at 37°C, followed by 4',6'-diamidino-2-phenylindole (DAPI) staining for 5 min. All samples were visualized with an Olympus BX60 microscope, and images were collected with a Hamamatsu ORCA-ER digital camera using Openlab 4.0.1 software and assembled with Adobe Photoshop 7.0. Levels were adjusted to enhance contrast.
Western blotting.
S2 cells with or without dsRNA treatment for 6 days were counted, spun down, and lysed in 1x sample buffer (2x sample buffer is a solution of 8.3% glycerol, 1.25% sodium dodecyl sulfate, 0.1 M Tris-HCl, pH 6.7, 0.083 mg/ml bromophenol blue, 50 µl/ml 2-mercaptoethanol) at a concentration of 5 x 104 cells/µl. Samples were boiled for 5 min and spun down at 14,000 rpm at 4°C for 20 min. Fifteen microliters of lysate per lane was loaded onto a 4 to 15% Tris-HCl gradient gel. For Western blotting of larvae, three third-instar larva equivalents in 2x sample buffer were loaded per lane (larvae were homogenized in an Eppendorf tube, boiled, and spun down to remove debris). Gels were transferred to nitrocellulose, blocked with 1% nonfat dry milk-0.05% Tween-1x PBS, and probed overnight at 4°C with guinea pig anti-MLE antibody at a 1:500 dilution, mouse anti-
-tubulin (catalog no. GTU-88; Sigma) at a 1:1,000 dilution, mouse anti-HP1 (catalog no. C1A9; Developmental Studies Hybridoma Bank) at a 1:2,000 dilution, or chicken anti-Zn72D serum (1:200 dilution). The Zn72D antibody was created against a Zn72D peptide, TYREHLEGQKHKKREASL. Donkey anti-guinea pig Cy3 (1:1,000 dilution), donkey anti-mouse Cy3 (1:500 dilution), and donkey anti-chicken Cy3 (1:500 dilution) (Jackson ImmunoResearch) were each used as a secondary antibody and were detected using a Typhoon 9400 instrument and quantitated using Quantity One software (Bio-Rad). MLE levels were normalized to that of HP1 or
-tubulin.
Flies. The 43S2 fly line was a gift from Helena Richardson, and its generation is described in the report by Brumby et al. (7). The mutation was identified by sequencing PCR products along the length of the Zn72D mutant gene. The GFP-Zn72D transgene was generated by using an Invitrogen Gateway system to clone Zn72D into pTGW. This construct was used to create transgenic flies (BestGene, Inc.). pTGW-Zn72D flies were crossed to w118 hsGal4 (III) flies (a gift from Pat O'Farrell), and third-instar larvae were heat shocked for 1 h to induce GFP-Zn72D expression.
qRT-PCR. Cells were treated with dsRNAs for 5 to 6 days (as described above for S2 cells; and Kc cells were incubated with dsRNA in serum-free medium for 1 h, and then twice the volume of complete Schneider's medium was added). Cells were Trizol extracted, treated with DNase I (Worthington), and phenol-chloroform extracted; RNA samples were quantitated; and 2.5-µg RNA samples were put into a 50-µl reverse transcription (RT) reaction. cDNA was diluted threefold, 2.5 µl was used in 20 µl quantitative (q)PCR assays using SYBR Master Mix (Applied Biosystems), and qPCR was done on an ABI 7300 instrument. Each sample was normalized to rp49 transcript levels and to the sample not treated with dsRNA.
qPCR primers. The following are the primers used for qPCR. Primers used for msl1 were QF1 (GAACAGGGCACACAAACGA) and QR1 (CCCCTGGGAAGTGCATTC); primers for msl2 were QF1 (GCATCCTTTGGTGCTTGTTC) and QR2 (GCTGCCCTGGAAGATATTGAA); primers for msl3 were QF2 (TGGCAAGCGAAAGGAAAA) and QR2 (GCCCCGGTTTCCCTTTAA); primers for mle (exons 2 to 3; red primers in Fig. 6) were QF1 (CGGAACACGCTAGGAGCTTT) and QR1 (TGAGCGCCGGCACAT); primers for mle (exons 3 to 4; blue primers in Fig. 6) were F1 (GATGAGGTGATTAAGGGTTTGG) and R3 (GAGGAATCTATACGGCTTAAG); the primer for mle (black primer in Fig. 6) was QF1adj (TGGGCCCGGAACACGC); primers for mof were QF3 (CAGGGAGACGGTCATCACA) and QR3 (CGGGATTTTCGCTTATATCGA); primers for Zn72D were QF2 (CGATGATAATCTGGACGATTCG) and QR2 (CGCCTACTGGCTTAATGTTGTC); primers for roX2 were QF1 (TTGCGCCTATGACAATCCTAA) and QR1 (GGCCATCCGAGCTACCTAAA); primers for mRpL16 were QF2 (TCAACACAGCCGGTCTTAAGTAT) and QR2 (GGCTGCTCCACATTCTGGTA); primers for rp49 were QF3 (GCCGTAATTGTCGTTTTTGG) and QR3 (CGAACAGCGCACGGACTA); primers for arm were arm-F (GCTGCTGAACGATGAGGATCA) and arm-R (CCAAAGCGGCTACCATCTGA); primers for CG14804 were CG14804-F (CTGAGCACAAGACGGCAGAG) and CG14804-R (GAGGGTCACGTTCACCTTGC); primers for RPII140 were RPII140-F (CACAATGGCGGCGGTT) and RPII140-R (ACGCAGATGTTCAGGCAGAGT) (51).
|
| RESULTS |
|---|
|
|
|---|
|
Zn72D is required in vivo for MSL complex localization and dosage compensation. Next, we determined whether Zn72D was required for proper MSL complex localization to the X chromosome in male flies. In the 43S2 line (7), a single base pair insertion causes a frame shift located before the first zinc finger domain of Zn72D (Fig. 1C). Polytene chromosomes isolated from third-instar larvae were stained with antibodies to MSL1 and MLE. Wild-type males showed the complete banding pattern of the MSL complex on the X chromosome, while Zn72D mutant males had significantly fewer bands (Fig. 2). These data demonstrate that Zn72D is required for the correct localization of the MSL complex to the X chromosome in vivo.
|
|
|
|
Zn72D promotes productive splicing of mle transcripts. As we attempted to determine the fate of the mle mRNA, it became clear that the entire mle transcript was not being turned over to the degree indicated in our original qRT-PCR experiments. Other regions of the mle transcript did not show the same dramatic decrease as the region assayed in the original qRT-PCR experiment (Fig. 6B). mle is alternatively spliced at the exon 2-exon 3 splice junction (33). One splice isoform produces an mRNA that directs production of full-length MLE (isoform 1, Fig. 6A). The other isoform employs a downstream splice donor, resulting in the production of an mRNA that is 342 nucleotides longer and contains several in-frame stop codons (isoform 2, Fig. 6A). Isoform 2 would direct the translation of a truncated MLE protein of 226 amino acids, instead of the full-length protein of 1,293 amino acids. The primers we used to quantify mle mRNA levels detected only isoform 1, as the forward primer spans the exon 2-exon 3 junction (Fig. 6A). To determine if the loss of Zn72D affected the abundance of both isoforms, we examined the exon 2-exon 3 junction by using primers that flank the intron and therefore amplify both isoforms plus unspliced RNA. In Zn72D–/– larvae and in Zn72D knockdown cells, the amount of isoform 1 decreased while the amount of isoform 2 increased (Fig. 6C and data not shown), suggesting that Zn72D regulates the relative amounts of the two mle isoforms rather than the absolute amount of mle mRNA. We performed Northern blotting as a second assay to measure the relative amounts of these two mle splice isoforms. Northern blotting indicated the presence of at least three mle transcripts (Fig. 6D), consistent with two poly(A) sites which are approximately 350 nucleotides apart (33) and the two splice sites that are also about 350 nucleotides apart. The identity of these transcripts was confirmed by using a probe that hybridizes to the region between the two poly(A) sites (data not shown). Upon Zn72D knockdown, the transcripts that could be attributed to splice isoform 1 decreased in abundance, while those that could be attributed to isoform 2 increased in abundance (Fig. 6D), indicating that Zn72D promotes the splicing of mle such that the full-length MLE protein is produced.
If the role of Zn72D in dosage compensation is to promote the productive splicing pattern of mle, then when an mle transcript that lacks introns is expressed, it should circumvent the requirement for Zn72D. To test this, we created a stable S2 cell line expressing the mle cDNA sequence tagged with Myc. Overexpressed Myc-MLE localized throughout the nucleus (Fig. 7A), consistent with the previous observation that overexpressed MLE localizes to all chromosomes in flies (46). MSL1 was still localized to the X chromosome in these Myc-MLE-overexpressing cells, indicating that the overexpressed protein did not interfere with MSL1 localization. When mle was knocked down in these cells, Myc-MLE expression was reduced, and MSL1 no longer appeared in a pattern consistent with enrichment on the X chromosome, indicating that even when MLE is overexpressed, the formation of the MSL complex is still sensitive to changes in the amounts of MLE. When Zn72D was knocked down, Myc-MLE levels did not decrease, and MSL1 localization was unaltered, indicating that the expression of the mle gene cDNA rescues the MSL localization defect observed when Zn72D is knocked down (Fig. 7A).
|
| DISCUSSION |
|---|
|
|
|---|
Zn72D is a zinc finger splicing factor. Zn72D contains three zinc fingers that are similar to the zinc finger in the U1 small nuclear ribonucleoprotein C (U1C). U1C binds the 5' splice site (5'ss) in a sequence-specific manner (13), and mutations in the zinc finger of U1C bypass the need for the DExH/D box helicase Prp28 to unwind the 5'ss and the U1 snRNA base pairing (9), suggesting that U1C stabilizes the 5'ss-U1 snRNA commitment complex. The similarity between the zinc fingers of Zn72D and those of U1C suggests the possibility that, like U1C, Zn72D might promote splicing through the regulation of the commitment complex formation between the 5'ss in pre-mRNAs and the U1 snRNA. Alternatively, Zn72D may recognize a 5'ss and inhibit its use in the splicing reaction, forcing the use of an alternative splice site. We were unable to detect an interaction between Zn72D and mle RNA, suggesting that Zn72D might instead play a more indirect role in 5'ss selection during mle splicing.
mle RNA is not subject to NMD. The splice isoform that is upregulated upon knockdown of Zn72D includes several in-frame premature translation termination codons (PTCs). PTCs can signal nonsense-mediated mRNA decay (NMD). The PTC-containing mle transcript was easily detected, by both Northern blotting and RT-PCR. In addition, this transcript was readily detected in cytoplasmic extracts by RT-PCR (data not shown), indicating that it is exported from the nucleus. When we overexpressed the intron-containing MLE transgene, a smaller Myc-tagged MLE protein product was expressed in addition to the full-length tagged MLE, suggesting that a protein can be produced from the PTC-containing spliced transcript. The increase in the levels of the PTC-containing mle transcript upon Zn72D knockdown is unlikely to be a consequence of the disruption of NMD, since there was a compensatory decrease in the other mle splice isoform and no increase in overall mle levels. This suggests that mle transcripts are not significantly affected by NMD and that Zn72D is required for productive splicing of mle. It is not yet clear how premature termination codon-containing transcripts are recognized as aberrant and are targeted for NMD in Drosophila. Unlike mammals and yeast, in which these transcripts are recognized based on the presence of exon junction complexes on the transcript downstream from the premature termination codon, Drosophila mRNAs do not require the exon junction complexes for NMD (18). As the PTC-containing mle transcript apparently lacks the Drosophila NMD signal, mle may be a transcript that is useful for investigating the NMD pathway in flies, as one can ask why the PTC-containing mle transcript avoids the fate of other transcripts that contain PTCs.
Does Zn72D link splicing to localization and translation? The closest mammalian homologue of Zn72D is ZFR; these proteins are 42% identical and 55% similar, and both proteins contain the same domain structure, with three zinc fingers followed by a DZF domain. ZFR was shown to be associated with chromosomes during meiosis, and it is required for normal development of the mouse embryo; homozygous Zfr mutants have gastrulation defects and die between 8 and 9 days of gestation (38, 39). Human ZFR was identified in a screen for Staufen2-interacting proteins and was implicated in nucleocytoplasmic shuttling of Staufen2 (14). Staufen1 and Staufen2 are dsRNA binding proteins that are implicated in the transport of mRNAs from the nucleus to cytoplasmic RNA granules (reviewed in references 30 and 42), which are clusters of ribosomes, translation factors, and mRNAs presumed to be incompetent for translation as they lack eIF4E, 4G, and tRNAs (32). Like its human counterpart, the Drosophila Staufen protein also plays a role in RNA localization: it is required for localization of the oskar mRNP complex to the posterior and of the bicoid mRNA to the anterior of the oocyte (reviewed in reference 27).
If Zn72D, like ZFR, is involved in localizing mRNP complexes within cells, this suggests it may be involved in linking splicing and mRNA localization. There is a precedent for the connection between splicing and RNA localization: splicing at a specific exon-exon junction of oskar is necessary for the proper localization of the oskar mRNA to the posterior (24), and members of the exon junction complex are also necessary for its localization (23, 35). Zn72D contains two putative nuclear export signals and a nuclear localization sequence, suggesting that Zn72D might participate in nucleocytoplasmic shuttling events. We did not observe any affect on localization for the dosage compensation complex upon RNAi-mediated knockdown of staufen (data not shown), so any potential homologous role of Zn72D in shuttling is likely mediated by other proteins.
| ACKNOWLEDGMENTS |
|---|
This work was supported by the ARCS Foundation (to K.A.W.) and the Hellman Foundation (to B.P.).
| FOOTNOTES |
|---|
Published ahead of print on 8 October 2007. ![]()
| REFERENCES |
|---|
|
|
|---|
2. Akhtar, A., D. Zink, and P. B. Becker. 2000. Chromodomains are protein-RNA interaction modules. Nature 407:405-409.[CrossRef][Medline]
3. Andrulis, E. D., J. Werner, A. Nazarian, H. Erdjument-Bromage, P. Tempst, and J. T. Lis. 2002. The RNA processing exosome is linked to elongating RNA polymerase II in Drosophila. Nature 420:837-841.[CrossRef][Medline]
4. Bai, X., A. A. Alekseyenko, and M. I. Kuroda. 2004. Sequence-specific targeting of MSL complex regulates transcription of the roX RNA genes. EMBO J. 23:2853-2861.[CrossRef][Medline]
5. Beckmann, K., M. Grskovic, F. Gebauer, and M. W. Hentze. 2005. A dual inhibitory mechanism restricts msl-2 mRNA translation for dosage compensation in Drosophila. Cell 122:529-540.[CrossRef][Medline]
6. Belote, J. M., and J. C. Lucchesi. 1980. Male-specific lethal mutations of Drosophila melanogaster. Genetics 96:165-186.
7. Brumby, A., J. Secombe, J. Horsfield, M. Coombe, N. Amin, D. Coates, R. Saint, and H. Richardson. 2004. A genetic screen for dominant modifiers of a cyclin E hypomorphic mutation identifies novel regulators of S-phase entry in Drosophila. Genetics 168:227-251.
8. Buscaino, A., T. Kocher, J. H. Kind, H. Holz, M. Taipale, K. Wagner, M. Wilm, and A. Akhtar. 2003. MOF-regulated acetylation of MSL-3 in the Drosophila dosage compensation complex. Mol. Cell 11:1265-1277.[CrossRef][Medline]
9. Chen, J. Y., L. Stands, J. P. Staley, R. R. Jackups, Jr., L. J. Latus, and T. H. Chang. 2001. Specific alterations of U1-C protein or U1 small nuclear RNA can eliminate the requirement of Prp28p, an essential DEAD box splicing factor. Mol. Cell 7:227-232.[CrossRef][Medline]
10. Dahlsveen, I. K., G. D. Gilfillan, V. I. Shelest, R. Lamm, and P. B. Becker. 2006. Targeting determinants of dosage compensation in Drosophila. PLoS Genet. 2:e5.[CrossRef][Medline]
11. Daneholt, B. 2001. Assembly and transport of a premessenger RNP particle. Proc. Natl. Acad. Sci. USA 98:7012-7017.
12. Demakova, O. V., I. V. Kotlikova, P. R. Gordadze, A. A. Alekseyenko, M. I. Kuroda, and I. F. Zhimulev. 2003. The MSL complex levels are critical for its correct targeting to the chromosomes in Drosophila melanogaster. Chromosoma 112:103-115.[CrossRef][Medline]
13. Du, H., and M. Rosbash. 2002. The U1 snRNP protein U1C recognizes the 5' splice site in the absence of base pairing. Nature 419:86-90.[CrossRef][Medline]
14. Elvira, G., B. Massie, and L. DesGroseillers. 2006. The zinc-finger protein ZFR is critical for Staufen 2 isoform specific nucleocytoplasmic shuttling in neurons. J. Neurochem. 96:105-117.[CrossRef][Medline]
15. Fagegaltier, D., and B. S. Baker. 2004. X chromosome sites autonomously recruit the dosage compensation complex in Drosophila males. PLoS Biol. 2:e341.[CrossRef][Medline]
16. Foley, E., and P. H. O'Farrell. 2004. Functional dissection of an innate immune response by a genome-wide RNAi screen. PLoS Biol. 2:E203.[CrossRef][Medline]
17. Fukunaga, A., A. Tanaka, and K. Oishi. 1975. Maleless, a recessive autosomal mutant of Drosophila melanogaster that specifically kills male zygotes. Genetics 81:135-141.
18. Gatfield, D., L. Unterholzner, F. D. Ciccarelli, P. Bork, and E. Izaurralde. 2003. Nonsense-mediated mRNA decay in Drosophila: at the intersection of the yeast and mammalian pathways. EMBO J. 22:3960-3970.[CrossRef][Medline]
19. Gebauer, F., M. Grskovic, and M. W. Hentze. 2003. Drosophila sex-lethal inhibits the stable association of the 40S ribosomal subunit with msl-2 mRNA. Mol. Cell 11:1397-1404.[CrossRef][Medline]
20. Gilfillan, G. D., C. Konig, I. K. Dahlsveen, N. Prakoura, T. Straub, R. Lamm, T. Fauth, and P. B. Becker. 2007. Cumulative contributions of weak DNA determinants to targeting the Drosophila dosage compensation complex. Nucleic Acids Res. 35:3561-3572.
21. Gu, W., X. Wei, A. Pannuti, and J. C. Lucchesi. 2000. Targeting the chromatin-remodeling MSL complex of Drosophila to its sites of action on the X chromosome requires both acetyl transferase and ATPase activities. EMBO J. 19:5202-5211.[CrossRef][Medline]
22. Gupta, V., M. Parisi, D. Sturgill, R. Nuttall, M. Doctolero, O. K. Dudko, J. D. Malley, P. S. Eastman, and B. Oliver. 2006. Global analysis of X-chromosome dosage compensation. J. Biol. 5:3.[CrossRef][Medline]
23. Hachet, O., and A. Ephrussi. 2001. Drosophila Y14 shuttles to the posterior of the oocyte and is required for oskar mRNA transport. Curr. Biol. 11:1666-1674.[CrossRef][Medline]
24. Hachet, O., and A. Ephrussi. 2004. Splicing of oskar RNA in the nucleus is coupled to its cytoplasmic localization. Nature 428:959-963.[CrossRef][Medline]
25. Hamada, F. N., P. J. Park, P. R. Gordadze, and M. I. Kuroda. 2005. Global regulation of X chromosomal genes by the MSL complex in Drosophila melanogaster. Genes Dev. 19:2289-2294.
26. Hilfiker, A., D. Hilfiker-Kleiner, A. Pannuti, and J. C. Lucchesi. 1997. mof, a putative acetyl transferase gene related to the Tip60 and MOZ human genes and to the SAS genes of yeast, is required for dosage compensation in Drosophila. EMBO J. 16:2054-2060.[CrossRef][Medline]
27. Johnstone, O., and P. Lasko. 2001. Translational regulation and RNA localization in Drosophila oocytes and embryos. Annu. Rev. Genet. 35:365-406.[CrossRef][Medline]
28. Kelley, R. L., V. H. Meller, P. R. Gordadze, G. Roman, R. L. Davis, and M. I. Kuroda. 1999. Epigenetic spreading of the Drosophila dosage compensation complex from roX RNA genes into flanking chromatin. Cell 98:513-522.[CrossRef][Medline]
29. Kelley, R. L., J. Wang, L. Bell, and M. I. Kuroda. 1997. Sex lethal controls dosage compensation in Drosophila by a non-splicing mechanism. Nature 387:195-199.[CrossRef][Medline]
30. Kiebler, M. A., R. P. Jansen, R. Dahm, and P. Macchi. 2005. A putative nuclear function for mammalian Staufen. Trends Biochem. Sci. 30:228-231.[CrossRef][Medline]
31. Kim, Y. J., P. Zuo, J. L. Manley, and B. S. Baker. 1992. The Drosophila RNA-binding protein RBP1 is localized to transcriptionally active sites of chromosomes and shows a functional similarity to human splicing factor ASF/SF2. Genes Dev. 6:2569-2579.
32. Krichevsky, A. M., and K. S. Kosik. 2001. Neuronal RNA granules: a link between RNA localization and stimulation-dependent translation. Neuron 32:683-696.[CrossRef][Medline]
33. Kuroda, M. I., M. J. Kernan, R. Kreber, B. Ganetzky, and B. S. Baker. 1991. The maleless protein associates with the X chromosome to regulate dosage compensation in Drosophila. Cell 66:935-947.[CrossRef][Medline]
34. Lee, C. G., T. W. Reichman, T. Baik, and M. B. Mathews. 2004. MLE functions as a transcriptional regulator of the roX2 gene. J. Biol. Chem. 279:47740-47745.
35. Le Hir, H., D. Gatfield, I. C. Braun, D. Forler, and E. Izaurralde. 2001. The protein Mago provides a link between splicing and mRNA localization. EMBO Rep. 2:1119-1124.[CrossRef][Medline]
36. Lucchesi, J. C., W. G. Kelly, and B. Panning. 2005. Chromatin remodeling in dosage compensation. Annu. Rev. Genet. 39:615-651.[CrossRef][Medline]
37. Lyman, L. M., K. Copps, L. Rastelli, R. L. Kelley, and M. I. Kuroda. 1997. Drosophila male-specific lethal-2 protein: structure/function analysis and dependence on MSL-1 for chromosome association. Genetics 147:1743-1753.[Abstract]
38. Meagher, M. J., and R. E. Braun. 2001. Requirement for the murine zinc finger protein ZFR in perigastrulation growth and survival. Mol. Cell. Biol. 21:2880-2890.
39. Meagher, M. J., J. M. Schumacher, K. Lee, R. W. Holdcraft, S. Edelhoff, C. Disteche, and R. E. Braun. 1999. Identification of ZFR, an ancient and highly conserved murine chromosome-associated zinc finger protein. Gene 228:197-211.[CrossRef][Medline]
40. Meller, V. H., P. R. Gordadze, Y. Park, X. Chu, C. Stuckenholz, R. L. Kelley, and M. I. Kuroda. 2000. Ordered assembly of roX RNAs into MSL complexes on the dosage-compensated X chromosome in Drosophila. Curr. Biol. 10:136-143.[CrossRef][Medline]
41. Meyer, B. J. 2000. Sex in the wormcounting and compensating X-chromosome dose. Trends Genet. 16:247-253.[CrossRef][Medline]
42. Miki, T., K. Takano, and Y. Yoneda. 2005. The role of mammalian Staufen on mRNA traffic: a view from its nucleocytoplasmic shuttling function. Cell Struct. Funct. 30:51-56.[CrossRef][Medline]
43. Nguyen, D. K., and C. M. Disteche. 2006. Dosage compensation of the active X chromosome in mammals. Nat. Genet. 38:47-53.[CrossRef][Medline]
44. Oh, H., J. R. Bone, and M. I. Kuroda. 2004. Multiple classes of MSL binding sites target dosage compensation to the X chromosome of Drosophila. Curr. Biol. 14:481-487.[CrossRef][Medline]
45. Rattner, B. P., and V. H. Meller. 2004. Drosophila male-specific lethal 2 protein controls sex-specific expression of the roX genes. Genetics 166:1825-1832.
46. Richter, L., J. R. Bone, and M. I. Kuroda. 1996. RNA-dependent association of the Drosophila maleless protein with the male X chromosome. Genes Cells 1:325-336.[Abstract]
47. Robishaw, J. D., and J. R. Neely. 1985. Coenzyme A metabolism. Am. J. Physiol. 248:E1-E9.[Medline]
48. Sass, H., and T. Pederson. 1984. Transcription-dependent localization of U1 and U2 small nuclear ribonucleoproteins at major sites of gene activity in polytene chromosomes. J. Mol. Biol. 180:911-926.[CrossRef][Medline]
49. Smith, E. R., A. Pannuti, W. Gu, A. Steurnagel, R. G. Cook, C. D. Allis, and J. C. Lucchesi. 2000. The Drosophila MSL complex acetylates histone H4 at lysine 16, a chromatin modification linked to dosage compensation. Mol. Cell. Biol. 20:312-318.
50. Soop, T., D. Nashchekin, J. Zhao, X. Sun, A. T. Alzhanova-Ericsson, B. Bjorkroth, L. Ovchinnikov, and B. Daneholt. 2003. A p50-like Y-box protein with a putative translational role becomes associated with pre-mRNA concomitant with transcription. J. Cell Sci. 116:1493-1503.
51. Straub, T., G. D. Gilfillan, V. K. Maier, and P. B. Becker. 2005. The Drosophila MSL complex activates the transcription of target genes. Genes Dev. 19:2284-2288.
52. Taipale, M., and A. Akhtar. 2005. Chromatin mechanisms in Drosophila dosage compensation. Prog. Mol. Subcell. Biol. 38:123-149.[Medline]
53. Weeks, J. R., S. E. Hardin, J. Shen, J. M. Lee, and A. L. Greenleaf. 1993. Locus-specific variation in phosphorylation state of RNA polymerase II in vivo: correlations with gene activity and transcript processing. Genes Dev. 7:2329-2344.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|